Roche's Vabysmo Shines in Q1 2024 as Tumor Pipeline Gets a Boost

Roche, a leading pharmaceutical company, has announced its first-quarter financial results for 2024, revealing a decline in overall sales but a remarkable performance by its eye disease drug Vabysmo. Despite facing strong competition from Regeneron and Bayer's high-dose Eylea, Vabysmo exceeded analyst expectations and achieved impressive revenue growth.

Roche's Q1 2024 financial report showed a decline in sales, with revenues totaling CHF 14.4 billion ($15.8 billion), reflecting a 6% decrease compared to Q1 2023. However, amidst this overall decline, Vabysmo, a dual-action drug for eye diseases, stood out with revenues of CHF 847 million ($927 million). This marked a remarkable 108% year-on-year growth, surpassing analysts' expectations of CHF 750 million.

Vabysmo's success is particularly noteworthy considering the recent approvals of high-dose versions of Eylea, a rival drug by Regeneron and Bayer, in the United States and the European Union, respectively. Despite these challenges, Roche reported that Vabysmo's sales remained unaffected since the beginning of the year. The drug has continued to capture market share in the treatment of age-related macular degeneration (AMD) and diabetic macular edema (DME), reaching 25% and 18% respectively, representing a 3% increase from the previous quarter.

Furthermore, since obtaining expanded labeling approval from the FDA in October last year, Vabysmo has secured an 8% market share in the treatment of retinal vein occlusion. Notably, over 40% of patients receiving Vabysmo treatment are first-time recipients of eye disease therapy, a significant increase from the 10% reported in the first quarter of the previous year.

Roche aims to expand Vabysmo's indications by including diabetic retinopathy as its fourth approved indication in the second half of this year. Additionally, the company plans to reintroduce Susvimo (ranibizumab), an ocular implant version of its anti-VEGF drug Lucentis, in Q3 2024. Susvimo had received approval in October 2021 but was recalled a year later due to leakage issues.

Apart from Vabysmo, another standout product in Roche's portfolio is Ocreuvus (ocrelizumab), a treatment for multiple sclerosis, which achieved sales of CHF 1.66 billion ($1.82 billion) in Q1 2024, representing an 8% YoY growth. With the potential approval of the injectable form of Ocrevus, Roche anticipates a significant increase in sales, potentially surpassing the $2 billion range.

During the quarter, Polivy (polatuzumab vedotin), a blood cancer treatment approved in 2019, and Phesgo (pertuzumab/trastuzumab), a breast cancer treatment approved in 2020, also experienced substantial sales growth. Polivy's sales increased by 70% to CHF 387 million ($424 million), while Phesgo's sales grew by 81% to CHF 249 million ($273 million).

Roche attributed the overall decline in Q1 revenues to the loss of income from its COVID-19 products. However, the company expects these effects to diminish by the end of Q2, paving the way for a recovery in revenue growth. Excluding COVID-19 products, Roche's sales for the quarter increased by 7%, supporting the company's guidance of achieving single-digit growth in 2024.

Roche's first-quarter performance in 2024 showcased a decline in overall sales but highlighted the exceptional success of Vabysmo in the competitive market for eye disease drugs. Despite facing strong challenges from high-dose versions of Eylea, Vabysmo surpassed expectations and achieved impressive revenue growth. With plans to expand Vabysmo's indications and reintroduce Susvimo, along with the continued success of Ocreuvus and other key products, Roche remains poised for future growth and innovation in the pharmaceutical industry.